Cardiol Therapeutics Inc.

NASDAQ:CRDL

Drug Manufacturers - Specialty & Generic

Healthcare
$0.95 -0.47%

-$0.01 today

Market cap
$114.64M
Beta
0.80
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $0.88High $1.71

Volume 0.31M

Average 0.68M

CRDL Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Cardiol Therapeutics Inc.NASDAQ: CRDL

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was CA$26.78K, compared with CA$0 a year earlier. Trailing-twelve-month cost of revenue was CA$52.73K.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near CA$26.78K or moves back toward the trailing-twelve-month quarterly average of CA$13.18K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$26.78K+3.2% QoQ
Last fiscal yearDec 2025
CA$0— YoY
LTMMar 2026
CA$52.73K-33.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

CAD · from the income statement

Latest · FY2025
0 CAD
Year-over-year change
—

Cost of Revenue vs competitors

How CRDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -33.2% is the 7th highest of 8, against a peer median of +26.1%.
CRDL Competitors
Cost of Revenue for CRDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCRInterCure Ltd.LTM Jun 2025₪202.51M ILS+4.0%+0.5%83.3%
ASRTAssertio Holdings, Inc.LTM Mar 2026$56.89M USD+26.1%+51.7%55.7%
HYPRHyperfine, Inc.LTM Mar 2026$7.48M USD+18.5%+4.9%48.8%
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
IMAImageneBio IncLTM Mar 2026$780K USD-95.0%-74.8%—
VANIVivani Medical, Inc.LTM Mar 2026$130K USD+46.1%——
MBOTMicrobot Medical Inc.LTM Mar 2026$115K USD+342.3%—109.5%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$52.73K CAD-33.2%——
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
CNTBConnect Biopharma Holdings LimitedFY2025$0 USD——0.0%
Peer median (excluding CRDL) —+26.1%+2.7%69.5%

Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue62.27K0000
Cost of Revenue174.26K162.23K187.38K00
Gross Profit(112K)(162.23K)(187.38K)00
Gross Margin-179.9%————
Research & Development8.59M13.99M10.73M14.01M14.02M
Selling, General & Admin21.86M16.34M11.55M25.89M20.2M
Operating Expenses30.46M30.33M22.29M40.28M34.32M
Depreciation & Amortization174.26K162.23K187.38K162.11K101.98K
EBITDA(24.84M)(22.66M)(21.04M)(36.52M)(33.72M)
EBITDA Margin-39891.0%————
Operating Income(30.57M)(30.49M)(22.47M)(40.28M)(34.32M)
Operating Margin-49092.4%————
Interest Income106K1.24M2.04M1.19M726.4K
Interest Expense00000
Other Income / Expenses5.56M7.68M1.25M3.6M497.42K
Income Before Tax(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Pre-Tax Margin-40170.9%————
Income Tax Expense00000
Net Income(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Net Margin-40170.9%————
EPS (Basic)(0.73)(0.49)(0.44)(0.51)(0.39)
EPS (Diluted)(0.73)(0.49)(0.44)(0.51)(0.39)
Weighted Avg Shares43.22M62.51M64.46M71.57M86.99M
Weighted Avg Shares (Diluted)43.22M62.51M64.46M71.57M86.99M

Cardiol Therapeutics Inc.

NASDAQ:CRDL

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.